iBio (IBIO) Income from Non-Controlling Interests (2016 - 2024)
iBio's (IBIO) quarterly Income from Non-Controlling Interests came in at $11000.0 in Q1 2024, down 31.25% year-on-year from $16000.0 in Q2 2023, and down 15.38% on a QoQ basis from $13000.0 in Q4 2023.
iBio (IBIO) Income from Non-Controlling Interests (2016 - 2024) Analysis & Trends
iBio (IBIO) has 9 years of Income from Non-Controlling Interests data on file, last reported at $11000.0 in Q1 2024.
- On a quarterly basis, Income from Non-Controlling Interests fell 31.25% year-over-year to $11000.0 in Q1 2024; TTM through Mar 2024 was $54000.0, a 68.75% increase from a year earlier, with the FY2023 full-year figure at $49000.0, up 5000.0% from the prior year.
- Income from Non-Controlling Interests for Q1 2024 stood at $11000.0, down from $13000.0 in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for IBIO reached as high as $16000.0 in Q4 2022 and fell as low as -$13000.0 in Q4 2020.
- Historically, Income from Non-Controlling Interests has averaged $5000.0 across 5 years, with a median of $5000.0 in 2021.
- Across the five-year window, Income from Non-Controlling Interests plunged 600.0% in 2020 and soared 85.71% in 2021, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at -$13000.0 in 2020, then surged by 92.31% to -$1000.0 in 2021, then surged by 1700.0% to $16000.0 in 2022, then decreased by 18.75% to $13000.0 in 2023, then dropped by 15.38% to $11000.0 in 2024.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were $11000.0 in Q1 2024, $13000.0 in Q4 2023, and $14000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | - |
| 2 | Nanobiotix | 1,912.31 Bn | 1,912.25 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.15 Bn | 462.36 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 123.00 Bn | 115.76 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.22 Bn | 61.47 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - | - |
| 8 | Argenx Se | 55.76 Bn | 50.57 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.70 Bn | 34.69 Bn | 959.66 Mn | - |
| 10 | iBio | 163.25 Mn | 163.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 11,000.00 |
| Dec 31, 2023 | 13,000.00 |
| Sep 30, 2023 | 14,000.00 |
| Jun 30, 2023 | 16,000.00 |
| Mar 31, 2023 | 16,000.00 |
| Dec 31, 2022 | 16,000.00 |
| Sep 30, 2021 | -1,000.00 |
| Jun 30, 2021 | -2,000.00 |
| Mar 31, 2021 | -1,000.00 |
| Dec 31, 2020 | -13,000.00 |
| Sep 30, 2020 | -7,000.00 |
| Jun 30, 2020 | -2,000.00 |
| Dec 31, 2019 | -2,000.00 |
| Sep 30, 2019 | -1,000.00 |
| Jun 30, 2019 | -1,000.00 |
| Mar 31, 2019 | -1,000.00 |
| Dec 31, 2018 | -1,000.00 |
| Sep 30, 2018 | -1,000.00 |
| Mar 31, 2018 | -1,000.00 |
| Dec 31, 2017 | -1,000.00 |